7-(tert-Butyl)-6-chloro-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine

Catalog No. :
ACHPTQ623
CAS No. :
252977-54-1
Molecular Formula :
C15H14ClFN4
Molecular Weight :
304.76

IUPAC Name:7-(tert-butyl)-6-chloro-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine

7-(tert-Butyl)-6-chloro-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$578.00Login to see priceInquiryInquiry
250mg95%$875.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7-(tert-Butyl)-6-chloro-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine
IUPAC Name7-(tert-butyl)-6-chloro-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine
MDL No.MFCD23136014
Molecular FormulaC15H14ClFN4
Molecular Weight304.76
SMILESFC1=CC=CC=C1C2=NN=C3C=C(C(C)(C)C)C(Cl)=NN32
InChI KeyKXRSWXZVHQRQTP-UHFFFAOYSA-N
Synonym7-tert-butyl-6-chloro-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazine;7-TERT-BUTYL-6-CHLORO-3-(2-FLUOROPHENYL)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE(WXG02064);1,2,4-Triazolo[4,3-b]pyridazine,6-chloro-7-(1,1-dimethylethyl)-3-(2-fluorophenyl)-;100838
CAS No.252977-54-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACHPTQ623 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHPTQ623 route product structure diagram
    ACHPTQ623252977-54-1
Inquiry

2. ACHPTQ623 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACHPTQ623 route product structure diagram
    ACHPTQ623252977-54-1
Inquiry

Comments (0)